Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
出版信息
Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200354. doi: 10.1212/NXI.0000000000200354. Epub 2024 Dec 4.
Abstract
摘要
相似文献
1
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.那他珠单抗6周给药方案与持续4周给药方案治疗复发缓解型多发性硬化症的药代动力学和药效学
Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200354. doi: 10.1212/NXI.0000000000200354. Epub 2024 Dec 4.
2
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.那他珠单抗 6 周给药与持续 4 周给药治疗复发缓解型多发性硬化症的药代动力学和药效学。
Neurol Neuroimmunol Neuroinflamm. 2024 Dec;11(6):e200321. doi: 10.1212/NXI.0000000000200321. Epub 2024 Oct 11.
3
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.NOVA 研究的探索性临床疗效和患者报告结局：静脉注射那他珠单抗 6 周给药与持续 4 周给药治疗复发缓解型多发性硬化症的随机对照研究。
Mult Scler Relat Disord. 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11.
4
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.在复发缓解型多发性硬化症患者中，从每周给药 4 周转换为每周给药 6 周与继续每周给药 4 周的比较（NOVA）：一项随机、对照、开放标签、3b 期试验。
Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25.
5
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.一项关于那他珠单抗治疗复发缓解型多发性硬化的随机研究。
Mult Scler. 2021 Dec;27(14):2240-2253. doi: 10.1177/13524585211003020. Epub 2021 Apr 6.
6
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.在从标准间隔到纳武利尤单抗延长间隔给药转换的复发缓解型多发性硬化症患者中，血清神经丝轻链没有增加。
Mult Scler. 2022 Nov;28(13):2070-2080. doi: 10.1177/13524585221108080. Epub 2022 Jul 20.
7
A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.一项评估那他珠单抗在多发性硬化症中多种给药途径的随机试验。
J Clin Pharmacol. 2016 Oct;56(10):1254-62. doi: 10.1002/jcph.707. Epub 2016 Mar 3.
8
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.在复发缓解型多发性硬化症中，与那他珠单抗、芬戈莫德和干扰素β相比，阿仑单抗的治疗效果：一项队列研究。
Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11.
9
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.复发缓解型多发性硬化症患者接受那他珠单抗治疗第一年期间的白质扩散变化
AJNR Am J Neuroradiol. 2016 Jun;37(6):1030-7. doi: 10.3174/ajnr.A4690. Epub 2016 Mar 10.
10
Effectiveness of 6-week dosing of Natalizumab versus continued 4-week treatment for Multiple Sclerosis: An observational registry-based study.那他珠单抗6周给药方案与持续4周治疗方案对多发性硬化症的疗效：一项基于观察性登记研究
Mult Scler Relat Disord. 2025 Feb;94:106297. doi: 10.1016/j.msard.2025.106297. Epub 2025 Jan 27.
本文引用的文献
1
Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.那他珠单抗 6 周给药与持续 4 周给药治疗复发缓解型多发性硬化症的药代动力学和药效学。
Neurol Neuroimmunol Neuroinflamm. 2024 Dec;11(6):e200321. doi: 10.1212/NXI.0000000000200321. Epub 2024 Oct 11.
Zotero 插件